https://www.zacks.com/stock/news/2204856/top-5-momentum-picks-for-january-after-a-fabulous-2023?cid=CS-ZC-FT-analyst_blog|investment_ideas-2204856
Jan 03, 2024 - We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.
zc:-6303957344621396969
0
https://www.zacks.com/stock/news/2199316/5-big-drug-stocks-that-may-continue-to-outperform-in-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199316
Dec 18, 2023 - Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
zc:8412019759005506131
0
https://www.fool.com/investing/2023/12/14/3-stocks-to-buy-before-2024-that-can-set-you-up/?source=iedfolrf0000001
Dec 14, 2023 - These stocks are still relatively cheap, but don't expect them to stay that way for long.
0
fool:759506756515710012
0
https://www.zacks.com/commentary/2195370/top-analyst-reports-for-chevron-sap-united-parcel-service?cid=CS-ZC-FT-research_daily-2195370
Dec 08, 2023 - Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), SAP SE (SAP) and United Parcel Service, Inc. (UPS).
zc:-2121452919798845299
0
https://www.zacks.com/stock/news/2195671/regeneron-regn-posts-positive-data-on-blood-cancer-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195671
Dec 08, 2023 - Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.
zc:9070898926774347693
0
https://www.zacks.com/stock/news/2195113/sanofi-sny-posts-upbeat-long-term-outlook-enhances-r-d-focus?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195113
Dec 07, 2023 - Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.
zc:1484433858443186251
0
https://www.zacks.com/stock/news/2193528/eyepoint-eypt-surges-178-on-upbeat-phase-ii-eye-disease-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193528
Dec 05, 2023 - EyePoint (EYPT) announces positive top-line data from the phase II study of its investigational candidate, EYP-1901, in the treatment of wet age-related macular degeneration. The stock rallies 178%.
zc:7798586859533673735
0